Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals Provides Update on Zepzelca® Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® in Gastroesophageal Adenocarcinoma and Zepzelca®
Jazz Pharmaceuticals to Present Research on Epidiolex® and Xywav® Oral Solution at the 2026 American Academy of Neurology Annual Meeting
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
SAGA Metals Highlights Radar Project's VTM Enriched Magnetic Concentrate up to 0.9% V2O5 Relative to Panzhihua, China Benchmark of 0.3% V2O5
Brixton Metals Commences Drilling for Maiden Tailings Mineral Resource Estimate at the Langis Silver Project
